Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00408902 · ClinicalTrials.gov registry record · Phase 2
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00408902: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00408902 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00408902, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving tandutinib after surgery may kill any tumor cells that remain after surgery.
Interventions
- OTHER laboratory biomarker analysis
- DRUG tandutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00408902
The ClinicalTrials.gov registry entry for NCT00408902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00408902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00408902 about?
NCT00408902 is a clinical study titled "Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer". This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving tandutinib af...
What is the current status of trial NCT00408902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00408902?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tandutinib (DRUG).
Who is sponsoring clinical trial NCT00408902?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.